Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced its participation in several upcoming virtual investment community events. Co-CEO and CFO James Martin will be featured in the Noble Capital Markets’ J.P. Morgan Healthcare Conference Takeaways, available January 26, discussing the biotechnology market and Cocrystal’s opportunities. Additionally, an update on the company’s influenza and COVID-19 antiviral programs will be presented in the C-Suite Interview Series by February 1. Cocrystal will also present at Sequire’s Virtual Biotechnology Conference on February 2 at 11:30 a.m. ET. Cocrystal specializes in developing antiviral therapeutics.
Cocrystal Pharma (Nasdaq: COCP) reported positive results from its Phase 1 study of CC-42344, an oral antiviral targeting influenza A. The study demonstrated favorable safety and tolerability, with no serious adverse events reported. Approximately 50% of subjects experienced mild adverse events, similar to the placebo group. The company plans to apply for regulatory approval to initiate a Phase 2a study in early 2023, targeting potential treatments for pandemic and seasonal influenza, aiming to address significant healthcare costs associated with the illness.
Cocrystal Pharma (Nasdaq: COCP) has presented progress on its CC-42344 influenza treatment at the World Antiviral Congress 2022. The Phase 1 study results indicate a favorable safety profile and potential clinical benefits against various influenza A strains. Plans are underway to report topline results by year-end 2022 and initiate a Phase 2a human challenge trial in 2023. The drug, a PB2 inhibitor, shows promise against seasonal and pandemic strains, notably with a high barrier to resistance.
Cocrystal Pharma (Nasdaq: COCP) announced positive results from the ongoing Phase 1 study of CC-42344, an oral antiviral for influenza A, showing a favorable safety profile in both single-ascending and multiple-ascending dose portions. The trial supports once-daily dosing, with topline results expected by the end of 2022. CC-42344 targets all major influenza A strains, demonstrating excellent antiviral activity. The company plans to submit an application for a Phase 2a human challenge study in early 2023, aiming to initiate the trial in the second half of 2023.
Cocrystal Pharma, Inc. (COCP) announced complete enrollment in its Phase 1 study for the antiviral candidate CC-42344 targeting influenza A, with topline results expected in late 2022. The company has selected CDI-988 as its lead candidate for SARS-CoV-2, planning to initiate a Phase 1 trial in early 2023. Financial results reveal an increase in R&D expenses to $3.9 million in Q3 2022 from $2.1 million in Q3 2021, and a net loss of $5.7 million. Cash reserves totaled $42.1 million, sufficient to fund operations for three years. Regulatory submissions for further clinical studies are anticipated in early 2023.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced participation in two investor conferences. On November 3, CFO James Martin will join a panel at the 2022 BioFlorida Annual Conference focusing on infectious diseases, held at Hyatt Regency Miami. Additionally, he will present a company overview at the Q4 Investor Summit on November 14 at Sheraton New York Time Square Hotel. A webcast of the Q4 Investor Summit will be available on the company’s IR Calendar page.
Cocrystal Pharma (Nasdaq: COCP) has been granted European patent EP3866778 for its oral PB2 inhibitor CC-42344, which may enhance treatment options against influenza when used with established antivirals like Tamiflu® and Xofluza®. The company recently completed enrollment in a Phase 1 study for CC-42344 and expects topline results soon. This patent represents a critical step in safeguarding their antiviral innovations in the EU and supports similar efforts globally.
Cocrystal Pharma (Nasdaq: COCP) has completed enrollment for its Phase 1 healthy volunteer study of CC-42344, a novel antiviral aimed at treating influenza A. This Phase 1 study, initiated in March 2022, assessed safety and pharmacokinetics. Following positive single-ascending-dose results announced in July, the company is moving forward with a Phase 2a human challenge study expected to start in H2 2023, pending regulatory approval. CC-42344 has shown effectiveness against seasonal strains and demonstrated a favorable safety profile.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that President and co-interim CEO Sam Lee, PhD, will present a company overview focusing on antiviral programs and clinical trials at the LD Micro Main Event XV. The presentation is scheduled for October 26, 2022, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time) at the Luxe Sunset Boulevard Hotel, Los Angeles. Interested parties can access the live webcast and archived presentation on the IR Calendar of the company website.
Cocrystal Pharma, Inc. (Nasdaq: COCP) will present data from its Phase 1 clinical trial of CC-42344, a novel antiviral targeting influenza A, at the upcoming World Antiviral Congress on December 1, 2022. Dr. Sam Lee, co-interim CEO, expressed excitement about sharing this first-in-human trial data, which aims to address both seasonal and pandemic influenza. The company plans to initiate a Phase 2a human challenge trial, leveraging advanced antiviral technology with a promising safety profile. The global influenza therapeutics market is expected to grow, reaching $9.5 billion by 2027.